Global Biosimilars Partnering Report 2010-2018

DUBLIN, Jan. 30, 2019 /PRNewswire/ --

The "Global Biosimilars Partnering Terms and Agreements 2010-2018" report has been added to ResearchAndMarkets.com's offering.

The Global Biosimilars Partnering Terms and Agreements 2010 to 2018 report provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Biosimilars partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Biosimilars technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual Biosimilars deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What are the precise rights granted or optioned?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sub-licensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Biosimilars dealmaking

2.1. Introduction
2.2. Biosimilars partnering over the years
2.3. Most active Biosimilars dealmakers
2.4. Biosimilars partnering by deal type
2.5. Biosimilars partnering by therapy area
2.6. Biosimilars partnering by industry sector
2.7. Deal terms for Biosimilars partnering
2.7.1 Biosimilars partnering headline values
2.7.2 Biosimilars deal upfront payments
2.7.3 Biosimilars deal milestone payments
2.7.4 Biosimilars royalty rates
2.8. The anatomy of an Biosimilars deal
2.8. a. Case study 1: RRD International & Dipexium Pharmaceuticals
2.8.b. Case study 2: Hospira & Cempra Pharmaceutical
2.8.c. Case study 3: Astellas & Optimer Pharmaceuticals

Chapter 3 - Leading Biosimilars deals

3.1. Introduction
3.2. Top Biosimilars deals by value

Chapter 4 - Most active Biosimilars dealmakers

4.1. Introduction
4.2. Most active Biosimilars dealmakers
4.3. Most active Biosimilars partnering company profiles

Chapter 5 - Biosimilars contracts dealmaking directory

5.1. Introduction
5.2. Biosimilars contracts dealmaking directory

Chapter 6 - Biosimilars dealmaking by technology type

Chapter 7 - Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 - Biosimilars deals by company A-Z
Appendix 2 - Biosimilars deals by stage of development
Appendix 3 - Biosimilars deals by deal type
Appendix 4 - Biosimilars deals by therapy area
Appendix 5 - Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/research/7hngg5/global?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-biosimilars-partnering-report-2010-2018-300786891.html

SOURCE Research and Markets